antibody peptide conjugates antibody-peptide conjugate - Peptide-drug conjugates: an emerging direction for the next generation ofpeptidetherapeutics powerful biopharmaceuticals that deliver highly toxic drugs or payloads Antibody-Peptide Conjugates: A New Frontier in Targeted Therapeutics

Approved peptide-drugconjugates The field of targeted drug delivery is rapidly evolving, with antibody-peptide conjugates emerging as a significant innovation. These sophisticated hybrid molecules consisting of an antibody linked to a peptide are poised to revolutionize therapeutic strategies, particularly in the realm of oncology and metabolic diseases.作者：Y Fei—Peptide drug conjugates (PDCs)have emerged as promising precision medicine toolsdue to their enhanced efficacy and safety profiles. Building upon the success of antibody-drug conjugates (ADCs), antibody-peptide conjugates offer unique advantages, including enhanced specificity, improved pharmacokinetic profiles, and potentially reduced off-target toxicities.

The fundamental principle behind antibody-peptide conjugates lies in harnessing the exquisite targeting capabilities of antibodies. Antibodies, specifically monoclonal antibodies, can recognize and bind to unique antigens expressed on the surface of diseased cells, such as cancer cells. By chemically or biologically linking a peptide to this antibody, researchers can create a delivery system that precisely directs therapeutic payloads to the intended sites of action. This conjugation process, which uses chemical and biological methods to create covalent connections between specific peptide segments and antibody structures, is a critical aspect of their development.

One of the key advantages of antibody-peptide conjugates over traditional treatments and even some earlier forms of targeted therapies is their ability to overcome limitations associated with smaller molecules or naked peptides.Antibody-Protein/Peptide Conjugate For instance, Peptide-drug conjugates (PDCs), which share similarities in their modular design, are often highlighted for their smaller size for deeper tissue penetration. While ADCs are recognized as powerful biopharmaceuticals that deliver highly toxic drugs or payloads, the incorporation of peptides can offer distinct benefits. For example, specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability due to reduced Fc dynamics, as demonstrated in research by Kiyoshi and colleaguesWe conjugate proteins, mainly antibodies, with drugs, peptides, dyes, or oligonucleotides to create antibody-drug conjugates or other protein conjugates.. Furthermore, the development of antibody-peptide inhibitor conjugates (APICs), which conjugates non-natural peptide inhibitors (NNPIs) with antibodies, represents a sophisticated approach to directly blocking the activity of specific cellular targets, such as cathepsins in cancer cells.

The therapeutic potential of antibody-peptide conjugates is vast and continues to be explored across various disease areas. In oncology, these conjugates can be designed to deliver cytotoxic agents directly to tumor cells, thereby minimizing damage to healthy tissues. This targeted approach is crucial for improving treatment efficacy and reducing the debilitating side effects often associated with conventional chemotherapySpecific peptide conjugation to a therapeutic antibody .... Research into antibody-peptide epitope conjugates (APEC), for instance, aims to redirect T-cell viral immunity against tumor cells, showcasing a novel immunotherapeutic strategy.

Beyond cancer, antibody-peptide conjugates are showing promise in the treatment of metabolic disorders. A notable example is the antibody-peptide conjugate known as MariTide. Studies have shown that MariTide can induce significant weight loss in individuals with obesity and type 2 diabetes, outperforming placebo. This therapeutic effect is attributed to the conjugate's ability to leverage the longer half-life of the antibody-peptide conjugate compared to standalone peptides or small molecule drugs, as highlighted in recent progress reportsAntibody–peptide conjugates deliver covalent inhibitors .... This sustained action is crucial for managing chronic conditions effectively.

The development of antibody-peptide conjugates is not without its challenges作者：D Wang·2025·被引用次数：25—As the most successful modality of drug conjugates,antibody-drug conjugates (ADCs) have been widely used for cancer treatments, exhibiting both .... Ensuring the stability of the conjugate, optimizing the linker chemistry for efficient payload release, and managing potential immunogenicity are critical considerations.Intracellular Delivery System for Antibody–Peptide Drug ... However, advancements in bioanalytical strategies for CMC characterization of these complex molecules are continuously addressing these hurdles. The ability to conjugate proteins, mainly antibodies, with drugs, peptides, dyes, or oligonucleotides allows for the creation of highly tailored therapeutic agents.

In summary, antibody-peptide conjugates represent a significant leap forward in precision medicine. By combining the targeting precision of antibodies with the functional versatility of peptides, these conjugates offer a promising platform for developing more effective and safer therapies. As research progresses and new conjugation strategies emerge, antibody-peptide conjugates are poised to become a cornerstone of future therapeutic interventions, offering new hope for patients battling a wide array of diseases, including antibody\u2013drug conjugates are powerful tools for combatting a wide array of cancers.Peptide–drug conjugates (PDCs): a novel trend of ... - PMC - NIH The ongoing exploration of novel antibody-peptide conjugates signifies a new paradigm for targeted therapies, building on the legacy of antibody-drug conjugates (ADCs) and advancing the field of peptide therapeutics.